Patents by Inventor Matthew ADAMOWICZ

Matthew ADAMOWICZ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Gene therapy for retinitis pigmentosa
    Patent number: 12201698
    Abstract: Provided herein are methods for treating retinitis pigmentosa using an AAV particles encoding miR-708. In one aspect, viral particles are administered to the eye of a human subject; for example, by subretinal injection. Viral particles comprising AAV5 capsids or mutants thereof are contemplated.
    Type: Grant
    Filed: July 22, 2021
    Date of Patent: January 21, 2025
    Assignee: GENZYME CORPORATION
    Inventors: Catherine O'Riordan, Matthew Adamowicz
  • Treatment of Dry Age-Related Macular Degeneration
    Publication number: 20240401082
    Abstract: The present disclosure provides gene therapy that targets complement pathways for treating dry age-related macular degeneration.
    Type: Application
    Filed: March 15, 2024
    Publication date: December 5, 2024
    Applicant: Genzyme Corporation
    Inventors: Matthew Adamowicz, Hao Chen, Amy Frederick, Christian Mueller, Catherine O’Riordan, Vaishnavi Rajagopal, John C. Reed, Michael John Storek
  • GENE THERAPY FOR RETINITIS PIGMENTOSA
    Publication number: 20220054657
    Abstract: Provided herein are methods for treating retinitis pigmentosa using an AAV particles encoding miR-708. In one aspect, viral particles are administered to the eye of a human subject; for example, by subretinal injection. Viral particles comprising AAV5 capsids or mutants thereof are contemplated.
    Type: Application
    Filed: July 22, 2021
    Publication date: February 24, 2022
    Inventors: Catherine O'RIORDAN, Matthew ADAMOWICZ
  • Gene therapy for retinitis pigmentosa
    Patent number: 11103598
    Abstract: Provided herein are methods for treating retinitis pigmentosa using an AAV particles encoding miR-708. In one aspect, viral particles are administered to the eye of a human subject; for example, by subretinal injection. Viral particles comprising AAV5 capsids or mutants thereof are contemplated.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: August 31, 2021
    Assignee: GENZYME CORPORATION
    Inventors: Catherine O'Riordan, Matthew Adamowicz
  • GENE THERAPY FOR RETINITIS PIGMENTOSA
    Publication number: 20200046851
    Abstract: Provided herein are methods for treating retinitis pigmentosa using an AAV particles encoding miR-708. In one aspect, viral particles are administered to the eye of a human subject; for example, by subretinal injection. Viral particles comprising AAV5 capsids or mutants thereof are contemplated.
    Type: Application
    Filed: July 3, 2019
    Publication date: February 13, 2020
    Inventors: Catherine O'RIORDAN, Matthew ADAMOWICZ
  • Gene therapy for retinitis pigmentosa
    Patent number: 10383953
    Abstract: Provided herein are methods for treating retinitis pigmentosa using an AAV particles encoding miR-708. In one aspect, viral particles are administered to the eye of a human subject; for example, by subretinal injection. Viral particles comprising AAV5 capsids or mutants thereof are contemplated.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: August 20, 2019
    Assignee: GENZYME CORPORATION
    Inventors: Catherine O'Riordan, Matthew Adamowicz
  • GENE THERAPY FOR RETINITIS PIGMENTOSA
    Publication number: 20170173183
    Abstract: Provided herein are methods for treating retinitis pigmentosa using an AAV particles encoding miR-708. In one aspect, viral particles are administered to the eye of a human subject; for example, by subretinal injection. Viral particles comprising AAV5 capsids or mutants thereof are contemplated.
    Type: Application
    Filed: March 20, 2015
    Publication date: June 22, 2017
    Inventors: Catherine O'RIORDAN, Matthew ADAMOWICZ